[Immunotherapy in high grade astrocytomas: principles and current state].
It is generally accepted that tumour development promotes a systemic response leading to protect the host against cancer. However, tumours may as well elicit a partial immunodeficiency to avoid the development of a complete and active immune response. Since Bloom's first studies on immunotherapy to treat high grade gliomas in 1960, many attempts have been made from different medical specialties to use the immune system as a weapon against a great diversity of cancers. Main objective of this study is to outline the basic features of the immune response inside the Central Nervous System, the strategies employed by astrocytic tumours to evade body defences, and to provide an extended literature review on research on immunotherapy, especially concerning its patho-physiology and the clinical results achieved till date.
Pinilla-Arias
D
D
Servicio de Neurocirugía. Hospital General Universitario Gregorio Marañón. Madrid.
Mateo-Sierra
O
O
Gutiérrez
F A
FA
Fernández-Carballal
C
C
Carrillo
R
R
D001254:Astrocytoma / Q000628:therapy*; D016207:Cytokines / Q000494:pharmacology / Q000627:therapeutic use; D005909:Glioblastoma / Q000628:therapy*; D006801:Humans; D007155:Immunologic Factors / Q000494:pharmacology / Q000627:therapeutic use*; D007167:Immunotherapy / Q000379:methods*; D007378:Interleukins / Q000378:metabolism; D008233:Lymphotoxin-alpha / Q000627:therapeutic use*
D016207:Cytokines; D007155:Immunologic Factors; D007378:Interleukins; D008233:Lymphotoxin-alpha